Franklin Street Advisors Inc Nektar Therapeutics Transaction History

Franklin Street Advisors Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 26, 2022	SELL	$10.83 - $18.41 $167,865 - $285,355	-15,500 Reduced 50.0%	15,500 $209,000
Q3 2021 Oct 22, 2021	BUY	$13.07 - $18.84 $202,585 - $292,020	15,500 Added 100.0%	31,000 $557,000
Q4 2020 Feb 01, 2021	SELL	$15.77 - $19.03 $157,700 - $190,300	-10,000 Reduced 39.22%	15,500 $264,000
Q3 2020 Oct 21, 2020	SELL	$16.59 - $24.79 $41,475 - $61,975	-2,500 Reduced 8.93%	25,500 $423,000
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $912,900 - $1.7 Million	-30,000 Reduced 51.72%	28,000 $920,000
Q3 2017 Oct 11, 2017	BUY	$17.79 - $24.0 $1.03 Million - $1.39 Million	58,000	58,000 $1.39 Million

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $193M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Franklin Street Advisors Inc , based on Form 13F filings with the SEC.

Stay updated on Franklin Street Advisors Inc with notifications on news.